Medicament for treating febrile bronchial asthma and chronic bronchitis

Abstract

The invention relates to a medicament for treating febrile bronchial asthma and chronic bronchitis. A solid oral preparation, such as a capsule, is prepared by the steps of mixing 1700-1900 parts of fructus forsythiae, 1400-1600 parts of plaster stone, 800-1000 parts of peach kernel, 200-240 parts of earthworm and 55-65 parts of thunberg fritillary bulb, soaking with cold water, reheating and decocting, filtering and concentrating as well as drying, and then crushing with 85-95 parts of prepared rheum officinale and 25-35 parts of platycodon grandiflorum into granular sensation free fine powder, and preparing the granular sensation free fine powder into solid oral preparation according to the conventional procedures. The medicament can be used for treating the febrile bronchial asthma and the chronic bronchitis, has double efficacy of clearing heat and reducing phlegm, descending qi and relieving asthma, resisting inflammation and relieving spasm (expanding bronchus), and has immunoregulation function to the asthma.

Description

technical field [0001] The invention relates to a medicament for treating respiratory system diseases, in particular to a medicament for treating febrile bronchial asthma and chronic bronchitis prepared by taking traditional Chinese medicine as a raw material. Background technique [0002] Bronchial asthma is a common disease characterized by recurrent wheezing, dyspnea, chest tightness, cough, and generally variable reversible airflow limitation, most of which can be relieved spontaneously or after treatment. The morbidity and mortality of asthma have been increasing year by year around the world for decades, and it is also a major cause of chronic disease morbidity and death worldwide. This phenomenon has attracted widespread attention from the World Health Organization, governments and clinicians. According to incomplete statistics, there are 150 million people suffering from asthma in the world, and more than 180,000 people die from asthma every year. The prevalence rate...

AI Technical Summary

Problems solved by technology

Most of the inhaled β-receptor agonists used in the past are quick-acting preparations with a short duration of action. Although the symptoms of asthma are temporarily controlled, the inflammatory basis of the disease is not shaken. On the contrary, the development of airway inflammation in asthma is masked by the temporary relief of symptoms

Images